RankAlpha logo
Back to Rankings

OCGN

OcugenB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The best bull argument is that Ocugen has moved from acute balance-sheet pressure toward a more credible operating runway, while management has laid out concrete late-stage milestones across OCU400, OCU410, and OCU410ST that could materially re-rate the stock if delivered [#SEC-8K-2026-05-05] [#SEC-8K-2026-05-07].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Convertible notes and potential conversion-related dilution can cap upside even after the runway reset [#SEC-8K-2026-05-07].
Momentum
92
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.10 · Bull $2.40 · Bear $0.55
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.43
Why
Momentum92 · Δ7d -
Value41 · Δ7d +0.1
Sentiment44 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
44
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 91.8 / Value 41.1 / Sentiment 44.2

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$450.23M
Beta
3.49
Shares Out
338.52M
P/E (TTM) · Derived
-5.9
P/S (TTM)
84.33
P/FCF (TTM) · Derived
-6.96
Rev YoY
+3.5%
EPS YoY
+11.4%
Gross Margin
+37.0%
Op Margin
-1112.9%
Net Debt
$14.57M
Current Ratio
1.86
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology